OraVerse® in Practice
A solution that's easy to incorporate
In a time when many new dental technologies require training, equipment and setup time, OraVerse is a solution that fits simply with the way you practice today.
- No additional training required
- Same injection site
- Same technique as the local anesthetic
- Easy dosing
- 1:1 cartridge ratio to local anesthetic
- Maximum recommended dose
- 2 cartridges for adults and adolescents 12 years of age and older
- 1 cartridge for patients 6-11 years of age and over 66 lbs.
- 1/2 cartridge for children 6-11 years of age and weighing 33-66 lbs.
Ideal for common restorative and periodontal maintenance procedures
- Cavity preparations
- Crown preparations and placement
- Inlays, onlays and veneers
- Non-surgical periodontal scaling and root planing
OraVerse is indicated for reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse is not recommended for use in children less than 6 years of age or weighing less than 15 kg (33 lbs).
Important Safety Information
In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents. See full prescribing information for details.
